Inify Laboratories extends payment and delivery for share issues

Inify Laboratories AB has announced a postponement of the final payment date for its proposed Private Placement and Repair Issue from November 12, 2025, to March 25, 2026. This extension aims to provide shareholders with additional time to secure necessary funds. Consequently, the new shares are now expected to be fully delivered to participants and tradable on Euronext Growth Oslo by March 30, 2026.

Inify Laboratories specializes in histopathology diagnostics, focusing on prostate cancer and gastroenterology, leveraging AI-assisted workflows for world-leading precision. The company's operations may be subject to the Swedish FDI Act, requiring potential investors to assess notification requirements to the Inspectorate of Strategic Products, especially if holding significant voting rights.